Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 5/20 | 0.34 |
| ▸ | CA9 | Q16790 | 5/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HCAR1 | Q9BXC0 | 3/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18081938 | 0.82 | PDE3B (0.38) | PDE3BPDE3ACRBNCA12CA9 | |
| SCHEMBL1104596 | 0.77 | PDE3B (0.37) | PDE3BPDE3ACA12CA9CA1 | |
| SCHEMBL13183286 | 0.76 | BRD4 (0.42) | MAPK1KDM4EALDH1A1 | |
| SCHEMBL16631557 | 0.74 | ADORA2A (0.37) | PDE3BPDE3ACA1KDM4EALDH1A1 | |
| SCHEMBL18081941 | 0.73 | GDA (0.32) | KDM4EALDH1A1 | |
| SCHEMBL18081796 | 0.71 | ALDH1A1 (0.37) | KDM4EALDH1A1 | |
| SCHEMBL18081766 | 0.71 | BRD4 (0.40) | PDE3BPDE3AKDM4EALDH1A1 | |
| SCHEMBL18081798 | 0.71 | JAK1 (0.41) | PDE3BPDE3AKDM4EALDH1A1 | |
| SCHEMBL18081946 | 0.70 | HPGD (0.33) | — | |
| SCHEMBL18081904 | 0.69 | NPC1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526239-B1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORP (KR) | 2021-11-03 | — | — | EP | disclosed |
| US-11162104-B2 | SCN9A antisense pain killer | OLIPASS CORPORATION (KR) | 2021-11-02 | — | — | US | disclosed |
| US-20190345202-A1 | ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2019-11-14 | — | — | US | disclosed |
| WO-2018069764-A1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2018-04-19 | — | — | WO | disclosed |
| US-9732110-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9675632-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160159843-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20160058783-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-9085599-B2 | 2′allene-substituted nucleoside derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-7615618-B2 | Oligonucleotides comprising a non-phosphate backbone linkage | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| EP-1651642-B1 | PNA MONOMER AND PRECURSOR | PANAGENE INC (KR) | 2009-11-04 | — | — | EP | disclosed |
| EP-1470114-B1 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | PANAGENE INC (KR) | 2009-08-19 | — | — | EP | disclosed |
| US-20090004138-A1 | Bicyclic Nucleosides and Nucleotides as Therapeutic Agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2009-01-01 | — | — | US | disclosed |
| US-7411065-B2 | Peptide nucleic acid monomers: diphenylmethyl, benzyl, alkylthioalkyl, or phenylthioalkyl esters of N-(1-[4-(2-benzothiazolyl-, 2-benzoxazolyl-, 2-benzofuranyl- or 2-benzothiophenyl-sulfonyl)-3-piperazinon-1-ylcarbonylmethyl]pyrimidon-4-yl)carbamic acids | PANAGENE, INC. (KR) | 2008-08-12 | — | — | US | disclosed |
| US-7371860-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2008-05-13 | — | — | US | disclosed |
| US-7371859-B2 | Peptide nucleic acid monomers; 1-(4-(benzothiazolyl-, benzoxazolyl-, benzofuranyl-, and benzothiophenyl- sulfonyl)piperidin-3-one-1-ylcarbonylmethyl)adenines; suitable for automatic and parallel synthesis; increased yields | PANAGENE, INC. (KR) | 2008-05-13 | — | — | US | disclosed |
| US-7211668-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2007-05-01 | — | — | US | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
| US-7179896-B2 | Method of making PNA oligomers | PANAGENE, INC. (KR) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | PDE3B 1568/4885PDE3A 1692/4885CRBN 2319/4885 |
| US-20160159843-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | PCNA, ENTPD5, NME2 | PDE3B 556/4885PDE3A 1042/4885CRBN 4461/4885 |
| US-20190345202-A1 | ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES | AR, NR5A1, NR5A2 | PDE3B 3824/4885PDE3A 3490/4885CRBN 3989/4885 |
| US-20090004138-A1 | Bicyclic Nucleosides and Nucleotides as Therapeutic Agents | SLC29A2, NT5C2, NUDT1 | PDE3B 857/4885PDE3A 1181/4885CRBN 4616/4885 |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | DERA, NT5C3B, DUT | PDE3B 4694/4885PDE3A 4456/4885CRBN 1444/4885 |
| US-11162104-B2 | SCN9A antisense pain killer | SCN9A, SCN7A, SCN8A | PDE3B 1105/4885PDE3A 1441/4885CRBN 4475/4885 |
| US-20160058783-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | PCNA, ENTPD5, NME2 | PDE3B 556/4885PDE3A 1042/4885CRBN 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.